Home › Scleroderma › New York
Scleroderma clinical trials in New York
11 studies for Scleroderma are looking for participants at sites in New York.
Cities in New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- NYU Langone Hospital - Long Island, Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Hospital for Special Surgery, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center-New York Presbyterian Hospital, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07497087A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Icahn School of Medicine at Mount Sinai, New York
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717Platform Clinical Study for Conquering Scleroderma
- Northwell Health, Great Neck
- Hospital for Special Surgery, New York
- Columbia University Medical Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Columbia University Irving Medical Center, New York
- University of Rochester, Rochester
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, New York
- Nkarta Investigational Site, Stony Brook
- Nkarta Investigational Site, Syracuse
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Aug 7, 2026 · NCT06733935A Study of AZD0120 in Autoimmune Diseases
- Research Site, New York
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Jul 28, 2026 · NCT07295847A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Montefiore Medical Center, New York
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
- Hospital for Special Surgery, New York
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Mar 27, 2026 · NCT03844061Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 7, 2025 · NCT05892614From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.